Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2021. The document serves as a transaction notification regarding a specific insider trade rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific securities transaction:
- Instrument: American Depositary Shares (ADSs)
- Transaction Price: $42.3800 per ADS
- Transaction Volume: 1,179.988 ADSs
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of notional ADSs within an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a transaction executed on December 7, 2021, on the New York Stock Exchange (XNYS) by Dr. H Barron, Chief Scientific Officer and President, R&D.
Investor Verification Points
- Verify the total number of ADSs held by Dr. H Barron post-transaction to assess insider ownership concentration.
- Confirm the market price of GSK ADSs on December 7, 2021, to validate the reported transaction price of $42.3800.
- Review the terms of the GSK Executive Supplemental Savings Plan to understand the mechanics of "notional" acquisitions.